Brokerages predict that Boston Scientific Co. (NYSE:BSX) will report earnings of $0.44 per share for the current quarter, according to Zacks Investment Research. Seven analysts have made estimates for Boston Scientific’s earnings. The highest EPS estimate is $0.45 and the lowest is $0.43. Boston Scientific reported earnings of $0.39 per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 12.8%. The business is scheduled to issue its next earnings report on Wednesday, February 5th.
According to Zacks, analysts expect that Boston Scientific will report full-year earnings of $1.57 per share for the current fiscal year, with EPS estimates ranging from $1.55 to $1.58. For the next year, analysts expect that the firm will post earnings of $1.79 per share, with EPS estimates ranging from $1.73 to $1.88. Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that follow Boston Scientific.
Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.39 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.01. Boston Scientific had a net margin of 10.49% and a return on equity of 23.10%. The company had revenue of $2.71 billion for the quarter, compared to analysts’ expectations of $2.68 billion. During the same quarter in the previous year, the firm posted $0.35 EPS. Boston Scientific’s revenue was up 13.1% on a year-over-year basis.
NYSE:BSX traded down $0.11 during trading hours on Tuesday, reaching $42.61. The stock had a trading volume of 3,198,849 shares, compared to its average volume of 7,092,164. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.77 and a current ratio of 1.14. The stock has a 50 day simple moving average of $41.09 and a 200 day simple moving average of $41.28. Boston Scientific has a 12-month low of $31.56 and a 12-month high of $43.84. The stock has a market cap of $59.54 billion, a P/E ratio of 28.99, a price-to-earnings-growth ratio of 2.42 and a beta of 0.78.
In related news, insider Halliday Hamish 4,000,000 shares of the company’s stock in a transaction that occurred on Friday, October 11th. Also, insider Williamson Scott bought 250,000 shares of Boston Scientific stock in a transaction on Monday, November 4th. The shares were bought at an average cost of $0.12 per share, with a total value of $30,000.00. Over the last quarter, insiders have sold 83,099 shares of company stock worth $3,427,785. 0.66% of the stock is currently owned by corporate insiders.
Several institutional investors have recently made changes to their positions in the company. Whittier Trust Co. raised its position in shares of Boston Scientific by 31.5% in the second quarter. Whittier Trust Co. now owns 1,069 shares of the medical equipment provider’s stock worth $46,000 after buying an additional 256 shares in the last quarter. Winslow Evans & Crocker Inc. boosted its position in shares of Boston Scientific by 28.4% during the 2nd quarter. Winslow Evans & Crocker Inc. now owns 1,220 shares of the medical equipment provider’s stock valued at $54,000 after acquiring an additional 270 shares during the last quarter. LS Investment Advisors LLC boosted its position in shares of Boston Scientific by 0.7% during the 3rd quarter. LS Investment Advisors LLC now owns 41,926 shares of the medical equipment provider’s stock valued at $1,706,000 after acquiring an additional 275 shares during the last quarter. Panagora Asset Management Inc. grew its holdings in shares of Boston Scientific by 0.5% during the second quarter. Panagora Asset Management Inc. now owns 57,341 shares of the medical equipment provider’s stock worth $2,464,000 after purchasing an additional 280 shares in the last quarter. Finally, Hanseatic Management Services Inc. grew its holdings in shares of Boston Scientific by 1.4% during the second quarter. Hanseatic Management Services Inc. now owns 20,714 shares of the medical equipment provider’s stock worth $890,000 after purchasing an additional 288 shares in the last quarter. 91.08% of the stock is currently owned by hedge funds and other institutional investors.
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Featured Story: Compound Interest
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.